statut_color,statut,statut_name,NCTId,eudraCT,CTIS,completion_year,clinical_trial_title,acronym,intervention_type
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00003606,,,2001,Phase III Randomized Study of Cisplatin and Etoposide With or Without Epirubicin and Cyclophosphamide for Extensive Stage Small Cell Lung Cancer,,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00003683,,,2002,Treatment of Sarcomatous Kidney Cancer That is Metastatic in Adults With Doxorubicin and Ifosfamide. Phase II Study,,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00002870,,,2002,"A RANDOMIZED, MULTI-CENTRE PHASE III TRIAL TO EVALUATE THE ROLE OF INTENSIFIED THERAPY WITH AUTOLOGOUS TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS IN ADVANCED OR METASTATIC BREAST CANCER RESPONDING TO INDUCTION CHEMOTHERAPY",,PROCEDURE
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00002566,,,2003,INTERNATIONAL RANDOMIZED STUDY FOR THE SALVAGE TREATMENT OF GERM CELL TUMOURS,,PROCEDURE
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00006050,,,2003,Chemotherapy Intra-Arterial Hepatic With Oxaliplatin Combined With Leucovorin Calcium and Fluorouracil IV,,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00006051,,,2005,Combination Chemotherapy Concurrent With Postoperative Radiotherapy Epidermoid Carcinoma of the Head and Neck at High Risk of Recurrence - Study of Feasibility,,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00003860,,,2005,Intensive Chemotherapy With Peripheral Blood Stem Cell Support for Small Cell Lung Cancer,,PROCEDURE
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00227708,,,2006,Phase II Trial Assessing the Impact on Instrumental and Daily Living Autonomy of a Chemotherapy Regimen With Bi-Weekly Docetaxel in the Treatment of Metastatic or Locally Advanced Non-Small Cell Lung Cancer in Patients Over the Age of 70,,PROCEDURE
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00005979,,,2007,Phase III Randomized Study of Intensive Adjuvant Chemotherapy for Resected Colon Cancer at High Risk of Recurrence,,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00066274,,,2007,"Randomized Phase II Study Evaluating Three Chemotherapies: [Irinotecan + Oxaliplatin (Irinox)], [Irinotecan + LV5FU2] and [Oxaliplatin + LV5FU2] as First Intention Treatment in Subjects With Metastatic Colorectal Cancer",,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00003652,,,2007,Intensification Therapy for Locally Advanced Epidermoid Cancer of the Anal Canal - Phase III Intergroup Study,,PROCEDURE
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00006111,,,2008,"Multicenter Study of the Quality of Life of Patients With Invasive Urothelial Cancer Treated With Conservative Surgery Followed by Cisplatin, Fluorouracil and Radiotherapy",,PROCEDURE
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00104689,,,2008,Phase II Trial Assessing the Impact on the Activity of Daily Living of an Oral Chemotherapy by Capecitabine Associated With an Intravenous Chemotherapy by Oxaliplatin as First Line Treatment of Metastatic Colorectal Adenocarcinoma of Patients Aged Over 70,,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00006119,,,2008,Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma,,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00054587,,,2009,"Randomized And Multicentric Opened Phase III Study Evaluating The Concomitant Administration Of Docetaxel 75MG/M2 and Epirubicine 75MG/M2 Versus FEC 100 In Non Metastatic With Positive Lymphatic Nodes Breast Cancer Subjects, And The Sequential Addition Of Herceptin In (HER2+++) And (HER2++ And FISH+) Subjects",,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00287846,,,2010,Multicentric Phase I/II Study Evaluating the Efficacy and Toxicity of Imatinib in Adult Patients With Aggressive Fibromatosis That Cannot be Treated by Surgery or Curative Radiotherapy,,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00112658,,,2010,Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients,,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00002883,,,2010,A PROSPECTIVE RANDOMISED TRIAL OF INDUCTION CHEMOTHERAPY WITH 5-FU CONTINUOUS IV INFUSION AND CISPLATIN VERSUS SURGERY IN RESECTABLE ADENOCARCINOMA OF THE LOW THIRD OF THE ESOPHAGUS AND CARDIOESOPHAGEAL JUNCTION,,PROCEDURE
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00003627,,,2011,"Phase III Randomized Study of Radiotherapy With or Without Cisplatin and Fluorouracil for Locally Advanced, Nonresectable Squamous Cell Cancer of the Oropharynx or Hypopharynx",,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00423696,2005-000070-43,,2011,"Phase II Randomized Study of First-Line Therapy Comprising Bevacizumab and Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil (FOLFIRI) Versus Bevacizumab and Irinotecan Hydrochloride and Capecitabine (XELIRI) in Patients With Unresectable Metastatic Colorectal Cancer [ACCORD]",,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00424203,,,2011,"Multicenter Pilot Clinical Study of Adjuvant Chemotherapy for Subjects Over 70 Years: Impact on the Independence and Quality of Life of the Administration of Anthracycline-Based Chemotherapy in Adjuvant Setting for Patients Presenting With Immediately Operable Breast Cancer, Hormone Receptor Negative (RH-), and Lymph Node Positive (pN+) or pN0 But of Scarff-Bloom-Richardson* Grade III and ‚â• 2cm [GERICO]",,PROCEDURE
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00104702,,,2011,Radio-Surgical Treatment of Breast Cancer of Women Aged Over 70: Phase II Trial of Feasibility and Reproducibility of a Concentrated and Focalized Radiotherapy,GERICO03,PROCEDURE
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00112697,,,2012,Randomized Phase II Trial Evaluating [Radiotherapy-Docetaxel-5 Fluorouracil] Association Versus [Radiotherapy-Docetaxel-Cisplatin] Association in Non Resecables First Line of Chemotherapy in Metastatics Pancreas Cancers Patients,,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00217607,,,2012,Multicentric Phase II Study Evaluating the Efficacy and Toxicity of Weekly Paclitaxel in Locally Advanced or Metastatic Soft Tissue Angiosarcomas That Cannot be Treated by Surgery,,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00513058,2005-005167-28,,2012,Phase I Study Evaluating the Combination of Lapatinib + Vinorelbine in Patients With Locally Advanced or Metastatic Breast Cancer Overexpressing HER2,,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00227669,,,2012,Randomized Phase II Study Evaluating the Efficacy of Gemcitabine Versus the Gemcitabine/Docetaxel Combination as Second Line Treatment in Metastatic or Relapsed and Inoperable Uterine or Soft Tissue Leiomyosarcomas,,DRUG
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT00861094,,,2012,Phase II-III Study Comparing Radiochemotherapy With the FOLFOX Regimen Versus Radiochemotherapy With 5FU-cisplatin (Herskovic Regimen) in First Line Treatment of Patients With Inoperable Oesophageal Cancer.,,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00055679,,,2013,"Phase III Randomized Study Of Adjuvant Fluourouracil, Epirubicin And Cyclophosphamide, In Women With Stage I Breast Cancer",,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00227747,,,2013,Randomized Phase III Trial Comparing in a Preoperative Schedule the Result of Two Concurrent Chemoradiation Schemes (45 Gy + Capecitabine vs 50 Gy + Capecitabine - Oxaliplatin) on the Rate of Sterilization of the Operative Specimen in Resectable Rectal Carcinomas T3-4 No-2 Mo,,PROCEDURE
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00534274,2005-005166-37,,2013,Study of Positron Emission Tomography With 3'-Deoxy-3'-[18F] Fluoro-thymidine ([18F]-FLT) for the Evaluation of Response to Neoadjuvant Chemotherapy for Cancers of the Breast,,OTHER
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT01262469,2009-015981-73,,2013,PHASE II STUDY Evaluating the Toxicity and Activity of the Combination Lapatinib + Capecitabine in Elderly Patients Aged 70 and Over With Metastatic Breast Cancer Over Expressing HER2,GERICO09,DRUG
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT00541008,,,2013,Phase II of Sunitinib (SUTENT¬Æ) in First Line for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma - SUPAP,,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00003650,,,2013,Phase III Study of Combination Chemotherapy in Children With T Cell and Pre-B Cell Non-Hodgkin's Lymphoma,,DRUG
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT01165385,,,2014,An Open Label Dose Escalation and Pharmacokinetic Phase I Study With Pazopanib in Combination With Cisplatin (CDDP) Every Three Weeks in Patients With Advanced Solid Tumors,PACIFIK,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT01620242,2011-004712-32,,2014,"A PHASE II, OPEN-LABEL, MULTICENTER TRIAL OF CABAZITAXEL IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER AFTER FAILURE OF CISPLATIN, CETUXIMAB AND TAXANES.",ORL03,DRUG
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT00967031,2008-001084-10,,2014,A Multicenter Phase II Clinical Trial Assessing the Efficacy of the Combination of Lapatinib and Capecitabine in Patients With Non Pretreated Brain Metastasis From HER2 Positive Breast Cancer,LANDSCAPE,OTHER
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT00104715,,,2015,Randomized Phase III Trial Comparing an Association of Hormonal Treatment and Docetaxel Versus the Hormonal Treatment Alone in Metastatic Prostate Cancers,,PROCEDURE
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT00104741,,,2015,Multicentre Randomized Trial Assessing the Efficacy of a Short Neoadjuvant and Concomitant Hormone Therapy to an Exclusive Curative Cornformational Radiotherapy of Locolized Prostate Cancer With Intermediate Prognosis,,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00003607,,,2015,"Phase III Randomized Study of Radiotherapy to the Prostate With or Without Radiotherapy to the Pelvis in Patients With Stage I, II, or III Adenocarcinoma of the Prostate",,RADIATION
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00056095,,,2016,Phase II Trial in Intrafamilial Allogeneic Cell Transplant in Patients With Metastatic Kidney Cancer,,PROCEDURE
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT01313377,2008-004560-39,,2016,Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts,PRODIGE 12,OTHER
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT02818725,2009-011882-10,,2017,"Intensified Methotrexate, Vinblastine, Doxorubicin and Cisplatin +/-Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma in Patients Without Harvey Nor Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations. Phase II Study",GETUG-AFU19,DRUG
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT01442649,2009-012942-22,,2017,"Phase II, Multicentric Randomized Trial, Evaluating the Efficacy of Fluoropyrimidine-based Standard Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab",,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT01919879,2012-000167-25,,2017,A Multicentric Randomized Phase II Trial Evaluating Dual Targeting of EGFR Using the Combination of Cetuximab and Afatinib Versus Cetuximab Alone in Patients With Chemotherapy Refractory wtKRAS Metastatic Colorectal Cancer,UCGI 25,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT01254513,,,2017,"Randomized Phase II Study Evaluating the Feasibility of a Chemotherapy With Docetaxel-Prednisone in a Weekly Schedule or Every 3 Weeks, for Castration-resistant Metastatic Prostate Cancer Elderly Patients (>=75), ""Vulnerable"" or ""Frail"" , as Defined by the Criteria of the International Society of Geriatric Oncology (SIOG)",GERICO10,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT01443065,2009-012797-12,,2018,MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma FNCLCC-FFCD-AGEO PRODIGE 17-ACCORD 20 Randomized Phase II Trial,MEGA,DRUG
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT01842321,2012-002525-29,,2018,A Phase II Trial Evaluating the Activity of Abiraterone Acetate Plus Prednisone in Patients With a Molecular Apocrine HER2-negative Locally Advanced or Metastatic Breast Cancer,AMA,DRUG
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT00629616,2006-006409-10,,2018,A Randomized Multicenter Phase II Study Identifying Hormone Sensitivity Profiles and Evaluating the Efficacy of Anastrozole and Fulvestrant in the Neo-adjuvant Treatment of Operable Breast Cancer in Postmenopausal Women.,NIMFEA,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00010244,,,2018,"Conformational, Curative Ratiotherapy For Prostate Cancer (NO, N-): Phase III Multicenter Study Of The Contribution To Survival Without Clinical Or Biological Change With A Dose Variation Of 15% (80 Gy VS 70 Gy)",,RADIATION
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT02505048,2015-000580-14,,2019,"A Single Arm, Open-label, Phase II Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature",RUBY,DRUG
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT01442662,2011-001308-36,,2019,Phase II Multicenter Study to Determine the Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas,LMS03,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT02393820,2012-004408-36,,2019,Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma,PACSA-ORL02,DRUG
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT00820547,2008-001807-53,,2019,Phase II Study Evaluating the Efficacy and Tolerance of Bevacizumab (Avastin) in HER2- Inflammatory Breast Cancer,Beverly1,DRUG
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT00630032,2006-006494-24,,2020,"Randomized, Open Label, Multicentric Phase III Evaluating the Benefit of a Sequential Regimen Associating FEC 100 and Ixabepilone in Adjuvant Treatment of Non Metastatic, Poor Prognosis Breast Cancer Defined as Triple-negative Tumor [HER2 Negative - ER Negative - PR Negative] or [HER2 Negative and PR Negative] Tumor; in Node Positive or Node Negative Patients.",TavIx,DRUG
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT02997995,2016-000764-42,,2020,A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible for Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration After 4-6 Weeks Exposure to Immune-Attractant,ULTIMATE,PROCEDURE
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT02400567,2014-002560-33,,2020,"Open-label, Randomized, Multicenter, International, Parallel Exploratory Phase II Study, Comparing 3 FEC-3 Docetaxel Chemotherapy to Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women",NeoPAL,DRUG
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT02363751,2013-001179-19,,2020,Prospective Phase II Study of Gemcitabine Plus Platinum Salt in Combination With Bevacizumab (Avastin¬Æ) for Metastatic Collecting Duct Carcinoma,BEVABEL,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,,2015-004117-24,,2021,A Phase II Safety Trial of Nivolumab in Patients with Metastatic Renal Cell Carcinoma Who Have Progressed During or After Prior Systemic Anti-Angiogenic Regimen,NIVOREN,DRUG (presumed)
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT01442935,2009-012813-22,,2021,"Phase II Multicentric Randomized Trial, Evaluating the Best Protocol of Chemotherapy, Associated With Targeted Therapy According to the Tumor KRAS Status, in Metastatic Colorectal Cancer (CCRM) Patients With Initially Non-resectable Hepatic Metastases",METHEP 2,DRUG
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT03164655,2016-001493-15,,2021,A Randomized Phase II Study Comparing Treatment Intensification With CIAH Plus Systemic Chemotherapy to Systemic Chemotherapy Alone in Patients With Liver-only Colorectal Metastases Considered Still Non Resectable After at Least Two Months of Systemic Induction Chemotherapy,SULTAN,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT03101046,2016-002429-12,,2021,Personalized Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic During Chemotherapy: A GETUG-AFU 28 Study,TACTIK,DRUG
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT01526135,2011-002026-52,,2021,"Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma",,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT02404935,2012-005139-99,,2021,Randomized Phase II Study of First-line FOLFIRI Plus Cetuximab for 8 Cycles Followed by Either Single-agent Cetuximab as Maintenance Therapy or Observation in Patients With Wild-type KRAS and NRAS Metastatic Colorectal Cancer,TIME,DRUG
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT03132038,2016-001794-32,,2021,"A Phase II, Multicenter, Non Randomized, Open Label Study of Nivolumab In Recurrent and/or Metastatic Salivary Gland Carcinoma of the Head and Neck",NISCAHN,DRUG
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT01415674,2010-024046-29,,2021,Multi-centric Randomized Phase II Study of Pre-operative Afatinib (BIBW2992) Aiming at Identifying Predictive and Pharmacodynamic Biomarkers of Biological Activity and Efficacy in Untreated Non-metastatic Head and Neck Squamous Cell Carcinoma Patients,PREDICTOR,DRUG
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT03013335,,,2021,A Phase II Safety Trial of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen,NIVOREN,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT03383679,2017-002284-18,2024-516638-36-00,2022,A Randomized Phase 2 Study in Patients With Triple-negative Androgen Receptor Positive Locally Recurrent (Unresectable) or Metastatic Breast Cancer Treated With Darolutamide or Capecitabine,START,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT02754011,,,2022,"Dose-escalation, Phase I Multicentric Trial, Evaluating the Combination of Ribociclib and Capecitabine in Locally Advanced or Metastatic Breast Cancer HER2 Negative in Patients Previously Treated With Anthracyclines and Taxanes",GEP14-LEECAP,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,,2017-000154-19,,2022,A phase II randomized trial comparing alpelisib and fulvestrant versus chemotherapy as maintenance therapy in patients with PIK3CA mutated advanced breast cancer,SAFIR PI3K,DRUG (presumed)
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT01780220,2011-004831-30,,2022,Safety and Efficacy of Radiotherapy Combined With a 6-month LH-RH Agonist and Abiraterone Hormone Therapy Treatment in Biochemically-relapsing Prostate Cancer Following Surgery,CARLHA,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT02551237,,,2022,A Phase III Study Evaluating Two Neoadjuvant Treatments Radiochemotherapy (5 Weeks - 50Gy+Capecitabine) and Radiotherapy (1week - 25Gy) in Patient Over 75 With Locally Advanced Rectal Carcinoma,NACRE,DRUG
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT00055731,,,2022,Phase III Randomized Study Of Adjuvant Hormonal Therapy With And Without Docetaxel And Estramustine In Patients With Advanced Prostate Cancer Or With A High Risk Of Relapse,,PROCEDURE
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT02701907,,,2022,Low Level of Genomic Alteration to Predict Exceptional and Unexpected Response to Targeted Therapies in Patients With Solid Tumors,EXPRESS,OTHER
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT03226756,2017-000424-10,,2022,A Safety Study of Nivolumab in Patients With Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN),TopNIVO,DRUG
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT03943667,2018-002886-21,,2022,A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma,GEMPAX,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT02444390,,,2022,Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women,SAFIR-TOR,PROCEDURE
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT03012581,2016-002257-37,,2023,Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types,AcS√©,DRUG
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT02034981,2013-000885-13,,2023,AcS√© CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.,AcS√©,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT03012620,2016-002260-14,,2023,Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types,AcS√©,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT02539537,2014-003510-82,,2023,A Randomized Phase III Trial Comparing Chemotherapy With Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma,NEOPAN,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00673335,2007-000687-24,,2023,Prevention of Breast Cancer by Letrozole in Post-menopausal Women Carrying a BRCA1/BRCA2 Mutation,LIBER,DRUG
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT00104676,2005-001072-13,,2023,A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors,,DRUG
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT02117167,2013-001653-27,,2023,Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: SAFIR02_Lung - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer,SAFIR02_Lung,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT02339532,,,2024,"Neoadjuvant Phase II Trial Combining [3 FEC 100 Followed by 3 Docetaxel Associated With Trastuzumab Plus Pertuzumab] or [6 Docetaxel, Carboplatin Associated With Trastuzumab Plus Pertuzumab] According to TOP2A Status in Patients With T1c Operable, HER2-positive Breast Cancer",NeoTOP,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT03518606,2017-001857-14,2024-518151-29-00,2024,A Phase I/II Basket Trial Evaluating a Combination of Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumour,MOVIE,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT03838263,2018-000626-60,,2024,"A Multicenter, Randomized, Open Label, Phase II Study Evaluating the Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer",IMMUNEBOOST,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,,2013-001800-13,,2024,"Neoadjuvant phase II trial combining [3 FEC 100 followed by 3 docetaxel associated with trastuzumab plus pertuzumab] or [6 docetaxel, carboplatin associated with trastuzumab plus pertuzumab] according to TOP2A status in patients with T1c operable, HER2-positive breast cancer. Identification of pathological Complete Response (pCR) predictive factors.",GEP13-NEOTOP,DRUG (presumed)
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT04357873,2019-003839-33,2023-510320-71-00,2024,Phase II Basket Trial Evaluating the Efficacy of a Combination of Pembrolizumab and Vorinostat in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma,PEVOsq,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,,2012-000142-35,,,A prospective randomised phase III study of androgen deprivation therapy with or without local  radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-na√Øve prostate cancer.,,DRUG (presumed)
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,,2019-004899-19,,,"Adjuvant PalbOciclib + LetrOzole combination for hormone receptor positive / HER2-negative, Intermediate Risk breast cancer",APOLON,DRUG (presumed)
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00769405,,,,Phase III Study Evaluating the Use of Systemic Chemotherapy and Chemohyperthemia Intraperitoneal Preoperatively (CHIP) and After Maximum Resection of Peritoneal Carcinomatosis Originating With Colorectal Cancer,,PROCEDURE
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00423475,,,,Phase III Randomized Study of Adjuvant Radiotherapy With Versus Without Concurrent Goserelin in Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer,,PROCEDURE
